Last reviewed · How we verify
NK cell preparation
At a glance
| Generic name | NK cell preparation |
|---|---|
| Also known as | CEL001 injection |
| Sponsor | Guangzhou Xiling Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
- Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors (PHASE1)
- Therapy for Children With Advanced Stage Neuroblastoma (PHASE2)
- A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus (PHASE1)
- Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer (PHASE1, PHASE2)
- Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy (PHASE2)
- Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma (PHASE2)
- A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NK cell preparation CI brief — competitive landscape report
- NK cell preparation updates RSS · CI watch RSS
- Guangzhou Xiling Biotechnology Co., Ltd. portfolio CI